A new method for the preparation of pure topiramate with a micron particle size

Document Type : Research Article


Department of Chemical Technology, Iranian Research Organization for Science and Technology (IROST), Tehran, Iran


Crude topiramate was prepared from the reaction between diacetonefructopyranose, sulfuric diamide, and 2-picoline. During a controlled processing the presence of Triton-X-100, crude topiramate in a methanol-water solvent, was converted to pure micron size topiramate particles. The factors affecting the purification and micronization of topiramate, such as solvent and anti-solvent type and concentration ratio, temperature, and mixing speed, were investigated. A mechanism for the preparation of topiramate was proposed based on the results of changes in the concentration of the raw materials and an investigation of the intermediates. In addition, the solubility rate of topiramate with different particle sizes has been determined.


  • A micron-sized topiramate sample was synthesized by using of Triton X-10.
  • The purification and reduction of the size of topiramate were performed in one step.
  • The kinetic solubility of topiramate was improved by size reduction.


[1] K. Gao, L. Ma, X. Wang, L. Zuou, X.F. Wang, Application of drug nanocrystal technologies on Oral drug delivery of poorly soluble drugs, Pharm. Res. 30 (2013) 307-324.
[2] J.B. Dressman, C. Reppas, In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs, Eur. J. Pharm. Sci. 11 Suppl. 2 (2000) S73-S80.
[3] M. Wang, M. Thanou, Targeting nanoparticles to cancer, Pharmacol. Res. 62 (2010) 90-99.
[4] A.T.M. Serajuddin, Solid dispersion of poorly-soluble drugs: early promises, subsequent problems, and recent breakthroughs, J. Pharm. Sci. 88 (1999) 1058-1066.
[5] M.E. Davis, M.E. Brewster, Cyclodextrin-based pharmaceutics: past, present and future, Nat. Rev. Drug Discov. 12 (2004) 1023-1035.
[6] J. Breitenbach, Melt extrusion: from process to drug delivery technology, Eur. J. Pharm. Biopharm. 54 (2002) 107-117.
[7] S.S. Davis, C. Washington, P. West, L. Illum, G. Liversidge, L. Sternson, R. Kirsh, Lipid emulsions as drug delivery systems, Ann. N. Y. Acad. Sci. 507 (1987) 75-88.
[8] K. Kawakami, T. Yoshikawa, T. Hayashi, Y. Nishihara, K. Masuda, Microemulsion formulation for enhanced absorption of poorly soluble drugs II in-vivo study, J. Control Release, 81 (2002) 75-82.
[9] D.B. Fenske, A.Chonn, P.R. Cullis, Liposomal nanomedicines: an emerging field, Toxicol. Pathol. 36 (2008) 21-29.
[10] V.P. Torchilin, Multifunctional nanocarriers, Adv. Drug Deliver. Rev. 64 (2012) 302-315.
[11] R.J. Aitken, M.Q. Chaudhry, A.B.A. Boxall, M. Hull, Manufacture and use of nanomaterials: current status in the UK and global trends, Occup. Med. 56 (2006) 300-306.
[12] K. Praveen, C. Singh, A study on solubility enhancement methods for poorly water-soluble drugs, Am. J. Pharmacol. Sci. 14 (2013) 67-73.
[13] S.K. Poornachary, G. Han, J.W. Kwek, P.S. Chow, R.B.H. Tan, Crystallizing micronized particles of a poorly water-soluble active pharmaceutical ingredient: nucleation enhancement by polymeric additives, Cryst. Growth Des. 16 (2016) 749-758.
[14] A.R. Mokarram, A. Kebriaeezadeh, M. Keshavarz, A. Ahmadi, B. Mohabat, Preparation and in-vitro evaluation of indomethacin nanoparticles, DARU J. of Pharm. Sci. 18 (2010) 185-192.
[15] H.P. Thakkar, B.V. Patel, S.P. Thakkar, Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement, J. Pharm. Bioallied Sci. 3 (2011) 426-434.
[16] J.P.J. Dhaval, M.P. Vikram, R.J. Rishad, R. Patel, Optimization of formulation parameters on famotidine nanosuspension using factorial design and the desirability function, Int. J. PharmTech Res. 2 (2010) 155-161.
[17] P.R.J. Khadka, H. Kim, I. Kim, J.Y. Kim, H. Kim, J.M. Cho, G. Yun, J. Lee, Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution, and bioavailability, Asian J. Pharma. Sci. 9 (2014) 304-316.
[18] J. Leleux, R.O. Williams, Recent advancements in mechanical reduction methods: particulate system, Drug Dev. Ind. Pharm. 3109 (2013) 1-12.
[19] N. Rasenack, B. W. Muller, Micron-size drug particles: common and novel micronization techniques, Pharm. Dev. Technol. 9 (2004) 1-13.
[20] T. Yajima, S. Itai, H. Hayashi. K. Takayama, T. Nagai, Optimization of size distribution of granules for tablet compression, Chem. Pharm. Bull. 44 (1996) 1056-1060.
[21] B.Y. Shekunov, P. Chattopadhyay, H.H.Y. Tang, A.H.L. Chow, Particle size analysis in pharmaceutics: principles, methods and applications, Pharm. Res. 24 (2007) 203-227.
[22] C.A. Maryanoff, L. Scott, K.L. Sorgi, U.S. Patent No. 5,387,700 (issued Feb 7, 1995).
[23] a) Food and Drug Administration, Center for Drug Evaluation and Research, Application Number 020505s038s039, 020844s032s034lbl. b) Ӧrn ALMARSSON, M.L. Peterson, J. Remenar, EP 1,485,388A2 (Issued Dec. 15, 2004).
[24] B.E. Maryanoff, S.O. Nortey, J.F. Gardocki, R.P. Shank, S.P. Dodgson, Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta -D-fructopyranose sulfamate and related compounds, J. Med. Chem. 30 (1987) 880-887.
[25] A. Ferrari, I. Tiraferri, L. Neri, E. Sternieri, Clinical pharmacology of topiramate in migraine prevention, Expert Opin. Drug Met. 7 (2011) 1169-1181.
[26] Food and Drug Administration, Center for Drug Evaluation and Research, Application Number 22580Orig1s000.
[27] B.A. Johnson, N. Ati-Daoud, Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients, Curr. Pharm. Design, 16 (2010) 2103-2112.
[28] L.H. Wang, C.T. Huang, U.S. Patent No. 8,748,594 (issued Jun. 10, 2014).
[29] D.P. Balwant, L.P. Kumar, P.A. Kumar, H.B. Prafulbhai, WO/2007/108009 (issued Sep. 9, 2007).
[30] H.P. Chawla, A.S. Chowdhary, S.M. Patel, WO/2007/099388 (issued Sep. 07, 2007).